[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534526":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":34,"locations":35,"responsibleParty":52,"collaborators":34,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":34,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":34,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":37,"whyStopped":34,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","Patients will have no intervention and will continue to have optimised medical therapy and follow-up appointments (currently 1 appointment every 3 months).",[13],"Diagnostic Test: Stress Cardiac Magnetic Resonance",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention group","EXPERIMENTAL","Patients will be prescribed vericiguat once a day for 6 months, starting at 2.5mg and titrated up to the full dose of 10mg per day (doubling of dose every 2 weeks) in addition to optimised medical therapy and standard follow-up like the control group",[19,13],"Drug: Vericiguat",[21,27],{"type":22,"name":23,"description":17,"armGroupLabels":24,"otherNames":25},"DRUG","Vericiguat",[15],[26],"Verquvo",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DIAGNOSTIC_TEST","Stress Cardiac Magnetic Resonance","All patients will have stress CMR examinations at recruitment and at the end of trial.",[9,15],[33],"Stress CMR",null,[36],{"facility":5,"status":37,"city":38,"state":34,"zip":34,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Hong Kong","HK",{"type":41,"coordinates":42},"Point",[43,44],114.17469,22.27832,{"lat":44,"lon":43},[47],{"name":48,"role":49,"phone":50,"phoneExt":34,"email":51},"Ming Yen Ng, BMBS","CONTACT","(852)22554524","myng2@hku.hk",{"type":53,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100534526","vericiguat-in-patients-with-coronary-microvascular-dysfunction-causing-stable-chest-pain-v-com-100534526",false,"NCT06239974","Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Randomised Controlled Trial of Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)","Inclusion Criteria:\n\n1. Stable recurrent chest pain.\n2. 40 to 75 years old.\n3. Have coronary computed tomography (CT) angiogram or catheter coronary angiogram within 6 months showing non-obstructive coronary artery disease (\\\u003C50% coronary artery stenosis or fractional flow reserve \\>0.8).\n4. Stress CMR MPR \\\u003C2.19 12 or Stress MBF \\\u003C2.19ml\u002Fg\u002Fmin 13.\n5. Female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP),or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.\n\nExclusion Criteria:\n\n1. Systolic blood pressure \\\u003C100 mm Hg.\n2. Concurrent use of soluble guanylate cyclase stimulators (eg. Riociguat), or phosphodiesterase type 5 inhibitors (eg. vardenafil, tadalafil, and sildenafil).\n3. Has known allergy or sensitivity to any soluble guanylate cyclase stimulator.\n4. On long-acting nitrates (eg. isosorbide mononitrate)\n5. Known cardiomyopathy, complex congenital heart disease, endocarditis or pericarditis.\n6. Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST elevation myocardial infarction (STEMI)) or coronary revascularization (coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)) within 60 days prior to randomisation, or indication for coronary revascularization at time of randomisation.\n7. Has symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days prior to randomisation.\n8. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m2\n9. Malignancy or other non-cardiac condition limiting life expectancy to \\\u003C3 years.\n10. Patient's with implanted devices which are not MRI compatible.","ALL","40 Years","75 Years",{"count":65,"type":66},94,"ESTIMATED","INTERVENTIONAL",[69],"NA","This is a randomised controlled trial to determine the effectiveness of Vericiguat to improve stress myocardial blood flow (MBF) and myocardial perfusion reserve as measured by cardiac magnetic resonance (CMR) imaging.",[72],"Chest Pain",[29],"2026-06-25",{"date":76,"type":77},"2026-06-29","ACTUAL",{"date":79,"type":77},"2024-09-01",{"date":81,"type":66},"2027-08-31",{"name":5,"class":6},1]